Evidence map›Paper›PMID 31975802›Full record

ArticleFocus (American Psychiatric Publishing)2016

Deconstructing Diabetes and Depression: Clinical Context, Treatment Strategies, and New Directions.

Jonathan M Gregory, Joshua D Rosenblat, Roger S McIntyre

Open access · greenAbstract read
In one paragraph

Article in Focus (American Psychiatric Publishing), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Observational
  3. [Mental disorders and diabetes mellitus (Update 2023)].Wiener klinische Wochenschrift · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jonathan M GregoryDr. Gregory is with the Department of Psychiatry, Western University, London, Ontario, Canada. Dr. Rosenblat and Dr. McIntyre are with the Department of Pharmacology and the Mood Disorder Psychopharmacology Unit, University Health Network, and the Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. McIntyre (e-mail: roger.mcintyre@uhn.ca).
Joshua D RosenblatDr. Gregory is with the Department of Psychiatry, Western University, London, Ontario, Canada. Dr. Rosenblat and Dr. McIntyre are with the Department of Pharmacology and the Mood Disorder Psychopharmacology Unit, University Health Network, and the Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. McIntyre (e-mail: roger.mcintyre@uhn.ca).
Roger S McIntyreDr. Gregory is with the Department of Psychiatry, Western University, London, Ontario, Canada. Dr. Rosenblat and Dr. McIntyre are with the Department of Pharmacology and the Mood Disorder Psychopharmacology Unit, University Health Network, and the Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. Send correspondence to Dr. McIntyre (e-mail: roger.mcintyre@uhn.ca).
Western University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression and diabetes are common, chronic, and frequently comorbid diseases that contribute substantially to global disability and mortality. Their relationship is bidirectional: depression increases the risk of developing type 2 diabetes mellitus (T2DM), and diabetes increases the risk of depression. Unhealthy lifestyles and poor self-care by patients with depression contribute to the increased T2DM risk. The psychosocial burden of a diabetes diagnosis and its eventual complications predispose diabetic patients to depressive symptoms. Neuroendocrine alterations and inflammation may underlie the increased risk of T2DM in depression but are also proposed as common causative factors for both illnesses. Screening for depression is essential in T2DM, and vice versa. Selective serotonin reuptake inhibitors effectively treat depression of patients with diabetes and positively influence glycemic control. Psychological interventions are effective for depressive symptoms, but their effect on glycemic control varies. Novel depression interventions targeting inflammation or insulin resistance underscore the common biological underpinnings of mood and metabolism.

Identifiers

PMID31975802
PMCPMC6519653
OpenAlexW2338620680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.